196 related articles for article (PubMed ID: 37558687)
41. Papillary and follicular neoplasms of the thyroid gland. Differential immunohistochemical staining with high-molecular-weight keratin and involucrin.
Liberman E; Weidner N
Appl Immunohistochem Mol Morphol; 2000 Mar; 8(1):42-8. PubMed ID: 10937048
[TBL] [Abstract][Full Text] [Related]
42. Human kidney injury molecule-1 (hKIM-1): a useful immunohistochemical marker for diagnosing renal cell carcinoma and ovarian clear cell carcinoma.
Lin F; Zhang PL; Yang XJ; Shi J; Blasick T; Han WK; Wang HL; Shen SS; Teh BT; Bonventre JV
Am J Surg Pathol; 2007 Mar; 31(3):371-81. PubMed ID: 17325478
[TBL] [Abstract][Full Text] [Related]
43. Comparative Evaluation of β-Catenin and E-Cadherin Expression in Liquid Aspiration Biopsy Specimens of Thyroid Nodules.
Isaeva AV; Zima AP; Saprina TV; Kasoyan KT; Popov OS; Brynova OV; Berezkina IS; Vasil'eva OA; Ryazantseva NV; Shabalova IP; Litvinova LS; Pak YD; Novitskii VV
Bull Exp Biol Med; 2016 Jun; 161(2):288-91. PubMed ID: 27383156
[TBL] [Abstract][Full Text] [Related]
44. Alpha-methyl CoA racemase expression in renal cell carcinomas.
Molinié V; Balaton A; Rotman S; Mansouri D; De Pinieux I; Homsi T; Guillou L
Hum Pathol; 2006 Jun; 37(6):698-703. PubMed ID: 16733210
[TBL] [Abstract][Full Text] [Related]
45. Expression of D2-40 in adjunct diagnosis of papillary thyroid carcinoma.
Wang SL; Li SH; Chen WT; Chai CY
APMIS; 2007 Aug; 115(8):906-10. PubMed ID: 17696946
[TBL] [Abstract][Full Text] [Related]
46. Expression of CD9/motility-related protein 1 (MRP-1) in renal parenchymal neoplasms: consistent expression in papillary and chromophobe renal cell carcinomas.
Kuroda N; Inoue K; Guo L; Miyazaki E; Hayashi Y; Naruse K; Toi M; Hiroi M; Shuin T; Enzan H
Hum Pathol; 2001 Oct; 32(10):1071-7. PubMed ID: 11679941
[TBL] [Abstract][Full Text] [Related]
47. Galectin-3: presurgical marker of thyroid follicular epithelial cell-derived carcinomas.
Saggiorato E; Aversa S; Deandreis D; Arecco F; Mussa A; Puligheddu B; Cappia S; Conticello S; Papotti M; Orlandi F
J Endocrinol Invest; 2004 Apr; 27(4):311-7. PubMed ID: 15233548
[TBL] [Abstract][Full Text] [Related]
48. CD10 expression is useful in the diagnosis of follicular carcinoma and follicular variant of papillary thyroid carcinoma.
Tomoda C; Kushima R; Takeuti E; Mukaisho K; Hattori T; Kitano H
Thyroid; 2003 Mar; 13(3):291-5. PubMed ID: 12729479
[TBL] [Abstract][Full Text] [Related]
49. Kidney-specific cadherin, a specific marker for the distal portion of the nephron and related renal neoplasms.
Shen SS; Krishna B; Chirala R; Amato RJ; Truong LD
Mod Pathol; 2005 Jul; 18(7):933-40. PubMed ID: 15696118
[TBL] [Abstract][Full Text] [Related]
50. Expression of vitamin D3 receptor in kidney tumors.
Liu W; Tretiakova M; Kong J; Turkyilmaz M; Li YC; Krausz T
Hum Pathol; 2006 Oct; 37(10):1268-78. PubMed ID: 16949927
[TBL] [Abstract][Full Text] [Related]
51. Immunohistochemical detection of p53 homolog p63 in solid cell nests, papillary thyroid carcinoma, and hashimoto's thyroiditis: A stem cell hypothesis of papillary carcinoma oncogenesis.
Burstein DE; Nagi C; Wang BY; Unger P
Hum Pathol; 2004 Apr; 35(4):465-73. PubMed ID: 15116328
[TBL] [Abstract][Full Text] [Related]
52. Aberrant expression of TfR1/CD71 in thyroid carcinomas identifies a novel potential diagnostic marker and therapeutic target.
Magro G; Cataldo I; Amico P; Torrisi A; Vecchio GM; Parenti R; Asioli S; Recupero D; D'Agata V; Mucignat MT; Perris R
Thyroid; 2011 Mar; 21(3):267-77. PubMed ID: 21323588
[TBL] [Abstract][Full Text] [Related]
53. Dysadherin: expression and clinical significance in thyroid carcinoma.
Sato H; Ino Y; Miura A; Abe Y; Sakai H; Ito K; Hirohashi S
J Clin Endocrinol Metab; 2003 Sep; 88(9):4407-12. PubMed ID: 12970317
[TBL] [Abstract][Full Text] [Related]
54. TROP-2 immunohistochemistry: a highly accurate method in the differential diagnosis of papillary thyroid carcinoma.
Bychkov A; Sampatanukul P; Shuangshoti S; Keelawat S
Pathology; 2016 Aug; 48(5):425-33. PubMed ID: 27311870
[TBL] [Abstract][Full Text] [Related]
55. Paxillin: application of immunohistochemistry to the diagnosis of chromophobe renal cell carcinoma and oncocytoma.
Kuroda N; Guo L; Toi M; Naruse K; Miyazaki E; Hayashi Y; Yoshikawa C; Ashida S; Shuin T; Enzan H
Appl Immunohistochem Mol Morphol; 2001 Dec; 9(4):315-8. PubMed ID: 11759057
[TBL] [Abstract][Full Text] [Related]
56. Co-expression and clinical utility of Snail and N-cadherin in papillary thyroid carcinoma.
Yang X; Shi R; Zhang J
Tumour Biol; 2016 Jan; 37(1):413-7. PubMed ID: 26219900
[TBL] [Abstract][Full Text] [Related]
57. Diagnostic utility of S100A1 expression in renal cell neoplasms: an immunohistochemical and quantitative RT-PCR study.
Rocca PC; Brunelli M; Gobbo S; Eccher A; Bragantini E; Mina MM; Ficarra V; Zattoni F; Zamò A; Pea M; Scarpa A; Chilosi M; Menestrina F; Bonetti F; Eble JN; Martignoni G
Mod Pathol; 2007 Jul; 20(7):722-8. PubMed ID: 17483815
[TBL] [Abstract][Full Text] [Related]
58. Fine-needle aspiration biopsy of papillary thyroid carcinoma: diagnostic utility of cytokeratin 19 immunostaining.
Nasser SM; Pitman MB; Pilch BZ; Faquin WC
Cancer; 2000 Oct; 90(5):307-11. PubMed ID: 11038428
[TBL] [Abstract][Full Text] [Related]
59. Overview of the 2022 WHO Classification of Thyroid Neoplasms.
Baloch ZW; Asa SL; Barletta JA; Ghossein RA; Juhlin CC; Jung CK; LiVolsi VA; Papotti MG; Sobrinho-Simões M; Tallini G; Mete O
Endocr Pathol; 2022 Mar; 33(1):27-63. PubMed ID: 35288841
[TBL] [Abstract][Full Text] [Related]
60. Tight junctions in thyroid carcinogenesis: diverse expression of claudin-1, claudin-4, claudin-7 and occludin in thyroid neoplasms.
Tzelepi VN; Tsamandas AC; Vlotinou HD; Vagianos CE; Scopa CD
Mod Pathol; 2008 Jan; 21(1):22-30. PubMed ID: 17962811
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
